Robert Wong was named Chief Accounting Officer of Retension Pharmaceuticals, Inc., effective November 2, 2026. As of October 28, 2026, Retension Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 23, 2026, naming 1 appointment (Form 8-K, October 23, 2026).
Sell to companies like Retension Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Retension Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-23. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Retension Pharmaceuticals, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-23 | In | Chief Accounting Officer | 2026-11-02 | 8-K, 2026-10-23 |
Selling to them or working with them? See who runs Retension Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Retension Pharmaceuticals, Inc. and the records around it.
Retension Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- IPO filing Oct 2026
- Who owns it
Companies that share a holder
- The B Group, Inc. also filed stake reports on 1 other company: NRx Pharmaceuticals, Inc. (Aug 2025)
- Laurence W. Lytton also filed stake reports on 28 other companies: Rank One Computing Corp (Aug 2026), MDxHealth SA (Aug 2026), AYTU BIOPHARMA, INC (Aug 2026)
Watch Retension Pharmaceuticals, Inc.
Get an email when Retension Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Retension Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Retension Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Retension Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Retension Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Robert Wong, appointed, effective 2026-11-02 (filed 2026-10-23).
New leaders reset buying decisions — get the Full Report on Retension Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Accounting Officer at Retension Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Accounting Officer at Retension Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Robert Wong, Chief Accounting Officer, effective 2026-11-02
On October 21, 2026, the Board of Directors of Retension Pharmaceuticals, Inc. (the "Company" or "Retension") appointed Robert Wong as Vice President, Chief Accounting Officer (Principal Accounting Officer) of the Company, effective as of November 2, 2026 (the "Commencement Date").
Tools for this story
Each opens in a new tab, filled in for Retension Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.